{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:32:49Z","timestamp":1787697169376,"version":"build-2784847793"},"reference-count":50,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MUR-Dipartimenti di Eccellenza 2023\u20132027 (DICUS 2.0)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Propranolol, largely prescribed as an antihypertensive and antiarrhythmic drug in pediatrics, is characterized by a bitter taste and an astringent aftertaste. Currently, the therapy requires crushing of tablets for adults and their dispersion in water many times a day, leading to loss of dosing accuracy, low palatability, and poor compliance for both patients and caregivers. Objectives: This work aimed to exploit cyclodextrin complexation by cogrinding to develop orally disintegrating tablets (ODTs) endowed with reliable dosing accuracy, good palatability and safety, ease of swallowability, and ultimately better compliance for both pediatric patients and caregivers. Results: Different formulation variables and process parameters were evaluated in preparing ODTs. The technological and morphological characterization and disintegration tests were performed according to official and alternative tests to select the ODT formulation based on the drug Hydroxypropyl-\u03b2-cyclodextrin (HP\u03b2CD) coground complex form containing Pearlitol\u00ae Flash as the diluent and 8% Explotab\u00ae as the superdisintegrant, which demonstrated the highest % drug dissolution in simulated saliva and acceptable in vitro palatability assessed by the electronic tongue, confirming the good taste-masking power of HP\u03b2CD towards propranolol. Conclusions: Such a new dosage form of propranolol could represent a valid alternative to the common extemporaneous preparations, overcoming the lack of solid formulations of propranolol intended for pediatric use.<\/jats:p>","DOI":"10.3390\/pharmaceutics16111351","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T04:28:43Z","timestamp":1729657723000},"page":"1351","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pediatric Orally Disintegrating Tablets (ODTs) with Enhanced Palatability Based on Propranolol HCl Coground with Hydroxypropyl-\u03b2-Cyclodextrin"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3643-6888","authenticated-orcid":false,"given":"Marzia","family":"Cirri","sequence":"first","affiliation":[{"name":"Department of Chemistry Ugo Schiff (DICUS), University of Florence, 50019 Sesto Fiorentino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9755-0911","authenticated-orcid":false,"given":"Paola A.","family":"Mura","sequence":"additional","affiliation":[{"name":"Department of Chemistry Ugo Schiff (DICUS), University of Florence, 50019 Sesto Fiorentino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7732-7381","authenticated-orcid":false,"given":"Francesca","family":"Maestrelli","sequence":"additional","affiliation":[{"name":"Department of Chemistry Ugo Schiff (DICUS), University of Florence, 50019 Sesto Fiorentino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Benedetti","sequence":"additional","affiliation":[{"name":"Department of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8064-3185","authenticated-orcid":false,"given":"Susanna","family":"Buratti","sequence":"additional","affiliation":[{"name":"Department of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"ref_1","unstructured":"(2024, April 07). EMA, European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Paediatric Committee (PDCO), Guideline on Pharmaceutical Development of Medicines for Pediatric Use Reference Number: EMA\/CHMP\/QWP\/805880\/2012 Rev. 2. Available online: https:\/\/www.ema.europa.eu\/en\/pharmaceutical-development-medicines-paediatric-use-scientific-guideline."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00431-019-03556-9","article-title":"Off-Label Use of Medicines in Neonates, Infants, Children, and Adolescents: A Joint Policy Statement by the European Academy of Paediatrics and the European Society for Developmental Perinatal and Pediatric Pharmacology","volume":"179","author":"Schrier","year":"2020","journal-title":"Eur. J. Pediatr."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zahn, J., Hoerning, A., Trollmann, R., Rascher, W., and Neubert, A. (2020). Manipulation of Medicinal Products for Oral Administration to Paediatric Patients at a German University Hospital: An Observational Study. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060583"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1080\/17425247.2021.2011856","article-title":"Orodispersible Tablets for Pediatric Drug Delivery: Current Challenges and Recent Advances","volume":"18","author":"Wiedey","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Golhen, K., Buettcher, M., Kost, J., Huwyler, J., and Pfister, M. (2023). Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041033"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"106377","DOI":"10.1016\/j.ejps.2023.106377","article-title":"Orally Disintegrating Drug Carriers for Paediatric Pharmacotherapy","volume":"182","author":"Kean","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1016\/j.xphs.2017.07.009","article-title":"Drug Delivery Innovations to Address Global Health Challenges for Pediatric and Geriatric Populations (Through Improvements in Patient Compliance)","volume":"106","author":"Boateng","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Ghourichay, M.P., Kiaie, S.H., Nokhodchi, A., and Javadzadeh, Y. (2021). Formulation and Quality Control of Orally Disintegrating Tablets (ODTs): Recent Advances and Perspectives. Biomed. Res. Int., 2021.","DOI":"10.1155\/2021\/6618934"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1080\/10837450.2019.1615090","article-title":"Orally disintegrating tablets and orally disintegrating mini tablets\u2014novel dosage forms for pediatric use","volume":"24","author":"Comoglu","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"ref_10","first-page":"21","article-title":"Current Developments in Orally Disintegrating Tablet Technology","volume":"2","author":"Nayak","year":"2011","journal-title":"J. Pharma. Educ. Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Chinwala, M. (2020). Recent Formulation Advances and Therapeutic Usefulness of Orally Disintegrating Tablets (ODTs). Pharmacy, 8.","DOI":"10.3390\/pharmacy8040186"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wagner-Hattler, L., Kiene, K., Bielicki, J., Pfister, M., Puchkov, M., and Huwyler, J. (2021). High Acceptability of an Orally Dispersible Tablet Formulation by Children. Children, 8.","DOI":"10.3390\/children8030194"},{"key":"ref_13","first-page":"S394","article-title":"Cyclodextrin Complexes: An Approach to Improve the Physicochemical Properties of Drugs and Applications of Cyclodextrin Complexes","volume":"2","author":"Vikas","year":"2018","journal-title":"Asian J. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","article-title":"Cyclodextrins: Structure, Physicochemical Properties and Pharmaceutical Applications","volume":"535","author":"Jansook","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Adamkiewicz, L., and Szeleszczuk, \u0141. (2023). Review of Applications of Cyclodextrins as Taste-Masking Excipients for Pharmaceutical Purposes. Molecules, 28.","DOI":"10.3390\/molecules28196964"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4172\/pharmaceutical-sciences.1000289","article-title":"Cetirizine Dihydrochloride, Beta-Cyclodextrin Inclusion Complex by Ethanol Kneading for Taste Masking","volume":"79","author":"Katewongsa","year":"2017","journal-title":"Indian. J. Pharm. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102245","DOI":"10.1016\/j.jddst.2020.102245","article-title":"Investigation of Hydroxypropyl-\u03b2-Cyclodextrin Inclusion Complexation of Two Poorly Soluble Model Drugs and Their Taste-Sensation\u2014Effect of Electrolytes, Freeze-Drying and Incorporation into Oral Film Formulations","volume":"61","author":"Alopaeus","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Commey, K.L., Nakatake, A., Enaka, A., Nakamura, R., Nishi, K., Tsukigawa, K., Ikeda, H., Yamaguchi, K., Iohara, D., and Hirayama, F. (2023). Study of the Structural Chemistry of the Inclusion Complexation of 4-Phenylbutyrate and Related Compounds with Cyclodextrins in Solution: Differences in Inclusion Mode with Cavity Size Dependency. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015091"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Commey, K.L., Enaka, A., Nakamura, R., Yamamoto, A., Tsukigawa, K., Nishi, K., Iohara, D., Hirayama, F., Otagiri, M., and Yamasaki, K. (2024). Development of \u03b1-Cyclodextrin-Based Orally Disintegrating Tablets for 4-Phenylbutyrate. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010082"},{"key":"ref_20","unstructured":"(2024, May 05). EMA\/CHMP\/333892\/2013 Committee for Human Medicinal Products (CHMP). Available online: www.ema.europa.eu\/en\/documents\/scientific-guideline\/questions-and-answers-cyclodextrins-used-excipients-medicinal-products-human-use_en.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jug, M., and Mura, P.A. (2018). Grinding as Solvent-Free Green Chemistry Approach for Cyclodextrin Inclusion Complex Preparation in the Solid State. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040189"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jpeds.2014.08.067","article-title":"Efficacy and Safety of High-Dose Propranolol for the Management of Infant Supraventricular Tachyarrhythmias","volume":"166","author":"Barton","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.31579\/2768-0487\/037","article-title":"Clinical Pharmacology of Propranolol in Infants and Children","volume":"3","author":"Pacifici","year":"2021","journal-title":"J. Clin. Lab. Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Cirri, M., Mura, P., Benedetti, S., and Buratti, S. (2023). Development of a Hydroxypropyl-\u03b2-Cyclodextrin-Based Liquid Formulation for the Oral Administration of Propranolol in Pediatric Therapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15092217"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijpharm.2013.09.013","article-title":"The STEP (Safety and Toxicity of Excipients for Paediatrics) Database: Part 2\u2014The Pilot Version","volume":"457","author":"Salunke","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2013.10.006","article-title":"Paediatric Oral Biopharmaceutics: Key Considerations and Current Challenges","volume":"73","author":"Batchelor","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rouaz, K., Chiclana-Rodr\u00edguez, B., Nardi-Ricart, A., Su\u00f1\u00e9-Pou, M., Mercad\u00e9-Frutos, D., Su\u00f1\u00e9-Negre, J.M., P\u00e9rez-Lozano, P., and Garc\u00eda-Montoya, E. (2021). Excipients in the Paediatric Population: A Review. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13030387"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.xphs.2018.11.013","article-title":"Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007","volume":"108","author":"Strickley","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"ref_29","unstructured":"Park, J.H., Holman, K.M., Bish, G.M., Grieger, D.G., Ramlose, D.S., Herman, C.J., and Hu, S.H. (2008). An Alternative to the USP Disintegration Test for Orally Disintegrating Tablets. Pharm. Technol., 32."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3797\/scipharm.0811-09-02","article-title":"Mouth Dissolving Tablets II: An Overview of Evaluation Techniques","volume":"77","author":"Shukla","year":"2009","journal-title":"Sci. Pharm."},{"key":"ref_31","unstructured":"Motohiro, O., Hayakawa, E., Ito, K., Tokuno, M., Morimoto, K., and Watanabe, K. (2001). Intrabuccally Rapidly Disintegrating Tablet. (US20010014340A1), Patent."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3746\/pnf.2022.27.4.354","article-title":"Recent Applications of Potentiometric Electronic Tongue and Electronic Nose in Sensory Evaluation","volume":"27","author":"Cho","year":"2022","journal-title":"Prev. Nutr. Food Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.aca.2019.05.024","article-title":"Critical Review of Electronic Nose and Tongue Instruments Prospects in Pharmaceutical Analysis","volume":"1077","author":"Wasilewski","year":"2019","journal-title":"Anal. Chim. Acta."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijpharm.2008.08.010","article-title":"Effects of Disintegration-Promoting Agent, Lubricants and Moisture Treatment on Optimized Fast Disintegrating Tablets","volume":"365","author":"Late","year":"2009","journal-title":"Int. J. Pharm."},{"key":"ref_35","unstructured":"(2024, May 17). ICH Harmonization for Better Health\u2014EMA\/CPMP\/ICH\/82072\/2006. ICHQ2 (R2) Guideline on Validation of Analytical Procedures. 24 March 2022. Available online: https:\/\/www.ema.europa.eu\/en\/ich-q2r2-validation-analytical-procedures-scientific-guideline."},{"key":"ref_36","unstructured":"(2024, May 17). European Pharmacopoeia, Council of Europe; 11th ed.; Strasbourg, 2022. Available online: https:\/\/www.edqm.eu\/en\/european-pharmacopoeia-ph.-eur.-11th-edition."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jsps.2015.01.015","article-title":"The Practical Approach to the Evaluation of Methods Used to Determine the Disintegration Time of Orally Disintegrating Tablets (ODTs)","volume":"23","author":"Brniak","year":"2015","journal-title":"Saudi Pharm. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/03639045.2010.505928","article-title":"Diclofenac Fast-Dissolving Film: Suppression of Bitterness by a Taste-Sensing System","volume":"37","author":"Cilurzo","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.3390\/s100403411","article-title":"Advanced Taste Sensors Based on Artificial Lipids with Global Selectivity to Basic Taste Qualities and High Correlation to Sensory Scores","volume":"10","author":"Kobayashi","year":"2010","journal-title":"Sensors"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/wics.101","article-title":"Principal Component Analysis","volume":"2","author":"Abdi","year":"2010","journal-title":"WIREs Comput. Stat."},{"key":"ref_41","first-page":"60","article-title":"Principal Component Analysis","volume":"7","author":"Mishra","year":"2017","journal-title":"Int. J. Livest. Res."},{"key":"ref_42","first-page":"24","article-title":"Development of Coprocessed Excipients","volume":"46","author":"Challener","year":"2022","journal-title":"Pharm. Technol."},{"key":"ref_43","unstructured":"(2024, May 18). Food and Drug Administration, Center for Drug Evaluation and Research, Dec. 2008, Guidance For Industry Orally Disin-Tegrating Tablets, Available online: www.fda.gov\/media\/70877\/download."},{"key":"ref_44","first-page":"287","article-title":"Effect of a Superdisintegrant on Disintegration of Orally Disintegrating Tablets Determined by Simulated Wetting Test and in Vitro Disintegration Test","volume":"77","author":"Sutthapitaksakul","year":"2022","journal-title":"Pharmazie"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.msec.2015.09.019","article-title":"Formulation of Cyclodextrin Inclusion Complex-Based Orally Disintegrating Tablet of Eslicarbazepine Acetate for Improved Oral Bioavailability","volume":"58","author":"Desai","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Al-Gethmy, H.A., Fahmy, U.A., Alhakamy, N.A., Ahmed, O.A.A., and El-Say, K.M. (2019). Optimization of the Factors Affecting the Absorption of Vardenafil from Oral Disintegrating Tablets: A Clinical Pharmacokinetic Investigation. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11010011"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajps.2018.05.001","article-title":"A Donepezil\/Cyclodextrin Complexation Orodispersible Film: Effect of Cyclodextrin on Taste-Masking Based on Dynamic Process and in Vivo Drug Absorption","volume":"14","author":"Liu","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Musuc, A.M., Anuta, V., Atkinson, I., Popa, V.T., Sarbu, I., Mircioiu, C., Abdalrb, G.A., Mitu, M.A., and Ozon, E.A. (2020). Development and Characterization of Orally Disintegrating Tablets Containing a Captopril-Cyclodextrin Complex. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12080744"},{"key":"ref_49","unstructured":"(2024, May 20). PEARLITOL\u00ae Flash Co-Processed Mannitol Starch. Available online: https:\/\/www.roquette.com\/innovation-hub\/pharma\/product-profile-pages\/pearlitol-flash-co-processed-mannitol-starch."},{"key":"ref_50","first-page":"S398","article-title":"Polyole","volume":"Volume 7","author":"Rosenplenter","year":"2007","journal-title":"Handbuch S\u00fc\u00dfungsmittel. Eigenschaften und Anwendung"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/11\/1351\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:18:16Z","timestamp":1760113096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/11\/1351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["pharmaceutics16111351"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16111351","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}